BCL‐2 functions as an activator of the AKT signaling pathway in pancreatic cancer
- 24 October 2007
- journal article
- research article
- Published by Wiley in Journal of Cellular Biochemistry
- Vol. 102 (5), 1171-1179
- https://doi.org/10.1002/jcb.21343
Abstract
BCL-2 is the prototypic anti-apoptotic protein involved in the regulation of apoptosis. Overexpression of BCL-2 is common in pancreatic cancer and confers resistance to the apoptotic effect of chemo- and radiotherapy. Although these cellular effects of BCL-2 are traditionally related to pathways involving the mitochondrial membrane, we sought to investigate whether BCL-2 is involved in other signaling pathways regulating cell survival and focused on AKT. We examined the effect of overexpression of BCL-2 in the MIA-PaCa-2 human pancreatic cancer cell line on the function and subcellular location of AKT. We observed that the stable subclones of MIA-PaCa-2 overexpressing BCL-2 demonstrated increased activity of AKT as well as IKK (a downstream target of AKT), increasing the transcriptional activity of NF-κB. Using immunoprecipitation techniques, we observed co-immunoprecipitation of AKT and BCL-2. Immunocytochemistry demonstrated co-localization of BCL-2 and AKT, which was abrogated by treatment with HA14-1, a small molecule inhibitor of BH-3-mediated protein interaction by BCL-2. Furthermore, treatment with HA14-1 decreased phosphorylation of AKT and increased sensitivity to the apoptotic effect of the chemotherapeutic agent, paclitaxel. These results demonstrate an additional mechanism of regulation of cell survival mediated by BCL-2, namely through AKT activation, in the MIA-PaCa-2 pancreatic cancer cell line. Therefore, directed inhibition of BCL-2 may alter diverse pathways controlling cell survival and overcome the apoptotic resistance that is the hallmark of pancreatic cancer. J. Cell. Biochem. 102: 1171–1179, 2007.Keywords
This publication has 33 references indexed in Scilit:
- Pten constrains centroacinar cell expansion and malignant transformation in the pancreasCancer Cell, 2005
- The PI 3-kinase/Akt signaling pathway is activated due to aberrant Pten expression and targets transcription factors NF-κB and c-Myc in pancreatic cancer cellsOncogene, 2004
- Protective role of Bcl-2 on β-amyloid-induced cell death of differentiated PC12 cells: reduction of NF-κB and p38 MAP kinase activationNeuroscience Research, 2004
- AKT inhibition is associated with chemosensitisation in the pancreatic cancer cell line MIA-PaCa-2British Journal of Cancer, 2003
- Role of NF-κB and Akt/PI3K in the resistance of pancreatic carcinoma cell lines against gemcitabine-induced cell deathOncogene, 2003
- Mitogenic and antiapoptotic role of constitutive NF‐κB/Rel activity in pancreatic cancerInternational Journal of Cancer, 2003
- Differential Mechanisms of Constitutive Akt/PKB Activation and Its Influence on Gene Expression in Pancreatic Cancer CellsJapanese Journal of Cancer Research, 2002
- IKKβ Is Required for Bcl-2-mediated NF-κB Activation in Ventricular MyocytesJournal of Biological Chemistry, 2002
- Suppression of transcription factor NF-κB activity by Bcl-2 protein in NIH3T3 cells: implication of a novel NF-κB p50-Bcl-2 complex for the anti-apoptotic function of Bcl-2European Journal of Cell Biology, 2000
- Bcl-2 down-regulates the activity of transcription factor NF-kappaB induced upon apoptosis.The Journal of cell biology, 1996